PharmChem, Inc. (PCHM)
USD 3.05
(0.0%)
USD 3.05
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 973.14 Thousand USD | -10.03% |
| 2022 | 1.08 Million USD | -29.97% |
| 2021 | 1.54 Million USD | -27.84% |
| 2020 | 2.14 Million USD | 31.1% |
| 2019 | 1.63 Million USD | 11.93% |
| 2018 | 1.45 Million USD | 18.39% |
| 2017 | 1.23 Million USD | 19.29% |
| 2016 | 1.03 Million USD | 0.0% |
| 2002 | -1.87 Million USD | 71.25% |
| 2001 | -6.52 Million USD | -450.46% |
| 2000 | 1.86 Million USD | -32.35% |
| 1999 | 2.75 Million USD | 336.45% |
| 1998 | 631 Thousand USD | 174.5% |
| 1997 | -847 Thousand USD | -302.63% |
| 1996 | 418 Thousand USD | -97.1% |
| 1995 | 14.4 Million USD | 166.67% |
| 1994 | 5.4 Million USD | -22.86% |
| 1993 | 7 Million USD | 11.11% |
| 1992 | 6.3 Million USD | -7.35% |
| 1991 | 6.8 Million USD | 70.0% |
| 1990 | 4 Million USD | 166.67% |
| 1989 | 1.5 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 193.1 Thousand USD | -35.02% |
| 2024 Q2 | 657.3 Thousand USD | 240.39% |
| 2023 Q1 | 158.46 Thousand USD | -31.96% |
| 2023 FY | 973.15 Thousand USD | -10.03% |
| 2023 Q4 | 297.15 Thousand USD | -2.06% |
| 2023 Q2 | 213.36 Thousand USD | 34.65% |
| 2023 Q3 | 303.4 Thousand USD | 42.2% |
| 2022 Q3 | 292.87 Thousand USD | 48.33% |
| 2022 Q1 | 342.04 Thousand USD | -23.21% |
| 2022 Q2 | 197.44 Thousand USD | -42.28% |
| 2022 FY | 1.08 Million USD | -29.97% |
| 2022 Q4 | 232.89 Thousand USD | -20.48% |
| 2021 FY | 1.54 Million USD | -27.84% |
| 2021 Q3 | 119.96 Thousand USD | -72.86% |
| 2021 Q2 | 442.05 Thousand USD | -17.69% |
| 2021 Q4 | 445.41 Thousand USD | 271.3% |
| 2021 Q1 | 537.07 Thousand USD | 0.0% |
| 2020 FY | 2.14 Million USD | 31.1% |
| 2019 FY | 1.63 Million USD | 11.93% |
| 2018 FY | 1.45 Million USD | 18.39% |
| 2017 FY | 1.23 Million USD | 19.29% |
| 2016 FY | 1.03 Million USD | 0.0% |
| 2003 Q1 | -588 Thousand USD | -386.83% |
| 2003 Q3 | -324 Thousand USD | 22.49% |
| 2003 Q2 | -418 Thousand USD | 28.91% |
| 2002 Q3 | -667 Thousand USD | -475.0% |
| 2002 Q2 | -116 Thousand USD | 43.41% |
| 2002 Q4 | 205 Thousand USD | 130.73% |
| 2002 FY | -1.87 Million USD | 71.25% |
| 2002 Q1 | -205 Thousand USD | -10.22% |
| 2001 FY | -6.52 Million USD | -450.46% |
| 2001 Q3 | -1.48 Million USD | 72.44% |
| 2001 Q2 | -5.37 Million USD | -928.74% |
| 2001 Q1 | -522 Thousand USD | -185.29% |
| 2001 Q4 | -186 Thousand USD | 87.43% |
| 2000 Q4 | 612 Thousand USD | -5.7% |
| 2000 Q3 | 649 Thousand USD | 5.7% |
| 2000 FY | 1.86 Million USD | -32.35% |
| 2000 Q2 | 614 Thousand USD | 18.99% |
| 2000 Q1 | 516 Thousand USD | 13.66% |
| 1999 Q3 | 2.4 Million USD | 71.43% |
| 1999 FY | 2.75 Million USD | 336.45% |
| 1999 Q2 | 1.4 Million USD | 0.0% |
| 1999 Q1 | 1.4 Million USD | 242.3% |
| 1999 Q4 | 454 Thousand USD | -81.08% |
| 1998 FY | 631 Thousand USD | 174.5% |
| 1998 Q1 | 1 Million USD | 553.59% |
| 1998 Q2 | 1.5 Million USD | 50.0% |
| 1998 Q3 | 1.5 Million USD | 0.0% |
| 1998 Q4 | 409 Thousand USD | -72.73% |
| 1997 Q4 | 153 Thousand USD | -49.0% |
| 1997 Q1 | 700 Thousand USD | 493.22% |
| 1997 FY | -847 Thousand USD | -302.63% |
| 1997 Q2 | 900 Thousand USD | 28.57% |
| 1997 Q3 | 300 Thousand USD | -66.67% |
| 1996 Q3 | 1.1 Million USD | -26.67% |
| 1996 Q4 | 118 Thousand USD | -89.27% |
| 1996 Q1 | 600 Thousand USD | -93.55% |
| 1996 FY | 418 Thousand USD | -97.1% |
| 1996 Q2 | 1.5 Million USD | 150.0% |
| 1995 Q4 | 9.3 Million USD | 1760.0% |
| 1995 Q1 | 1.5 Million USD | 25.0% |
| 1995 Q2 | 9.7 Million USD | 546.67% |
| 1995 Q3 | 500 Thousand USD | -94.85% |
| 1995 FY | 14.4 Million USD | 166.67% |
| 1994 Q3 | 100 Thousand USD | -98.81% |
| 1994 Q4 | 1.2 Million USD | 1100.0% |
| 1994 Q2 | 8.4 Million USD | 663.64% |
| 1994 Q1 | 1.1 Million USD | 1200.0% |
| 1994 FY | 5.4 Million USD | -22.86% |
| 1993 Q1 | 7.4 Million USD | 144.58% |
| 1993 Q2 | 100 Thousand USD | -98.65% |
| 1993 Q3 | 4.3 Million USD | 4200.0% |
| 1993 Q4 | -100 Thousand USD | -102.33% |
| 1993 FY | 7 Million USD | 11.11% |
| 1992 Q3 | 6.8 Million USD | -5.56% |
| 1992 Q1 | 6.3 Million USD | 145.99% |
| 1992 Q2 | 7.2 Million USD | 14.29% |
| 1992 FY | 6.3 Million USD | -7.35% |
| 1992 Q4 | -16.6 Million USD | -344.12% |
| 1991 FY | 6.8 Million USD | 70.0% |
| 1991 Q1 | 4.3 Million USD | 142.57% |
| 1991 Q2 | 6.6 Million USD | 53.49% |
| 1991 Q3 | 6.5 Million USD | -1.52% |
| 1991 Q4 | -13.7 Million USD | -310.77% |
| 1990 Q3 | 3.9 Million USD | 0.0% |
| 1990 Q4 | -10.1 Million USD | -358.97% |
| 1990 Q2 | 3.9 Million USD | 2.63% |
| 1990 Q1 | 3.8 Million USD | 148.1% |
| 1990 FY | 4 Million USD | 166.67% |
| 1989 Q1 | 2.5 Million USD | 0.0% |
| 1989 Q3 | 2.6 Million USD | 0.0% |
| 1989 Q4 | -7.9 Million USD | -403.85% |
| 1989 FY | 1.5 Million USD | 0.0% |
| 1989 Q2 | 2.6 Million USD | 4.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | 178.353% |
| Arrayit Corporation | -3.62 Million USD | 126.864% |
| Atlantic International Corp. | -5.73 Million USD | 116.976% |
| Biocept, Inc. | -31.98 Million USD | 103.043% |
| Bioqual, Inc. | -19.63 Thousand USD | 5055.428% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | 226.032% |
| DermTech, Inc. | -103.73 Million USD | 100.938% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 99.961% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 104.672% |
| iMD Companies, Inc. | -175.44 Thousand USD | 654.67% |
| IDenta Corp. | -1499.00 USD | 65019.746% |
| Interpace Biosciences, Inc. | 2.8 Million USD | 65.294% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -2415.242% |
| InVitro International | -25.33 Thousand USD | 3940.511% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 113.664% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 1774.606% |
| Medical Imaging Corp. | -819.48 Thousand USD | 218.752% |
| NovelStem International Corp. | -3.52 Million USD | 127.601% |
| Optigenex Inc. | 1.39 Million USD | 30.031% |
| Proteome Sciences plc | -1.62 Million USD | 160.034% |
| Response Genetics, Inc | -21.37 Million USD | 104.552% |
| Rennova Health, Inc. | -1.4 Million USD | 169.04% |
| RushNet, Inc. | -684.7 Thousand USD | 242.126% |
| ScreenPro Security Inc. | -2.59 Million USD | 137.538% |
| Stella Diagnostics Inc. | -11.42 Million USD | 108.516% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 112.562% |
| Todos Medical Ltd. | -9.74 Million USD | 109.983% |